Takeda acquisition spree may continue

|About: Takeda Pharmaceutical Co.,... (TAK)|By:, SA News Editor

Japan's Takeda Pharmaceutical (OTCPK:TKPYY) is willing to bolster its drug portfolio through fresh acquisitions after agreeing on Monday to buy Ariad Pharmaceuticals for $5.2B.

"Should the right deal come along we have the capacity," CFO James Kehoe declared.

At the end of its last business year that ended on March 31, Takeda had ¥438B ($3.8B) in cash and cash equivalents.

Subscribe for full text news in your inbox